BioTransplant Incorporated's 2002 First Quarter Results Conference Call to be Broadcast Live Over the Web May 13.Business, Health, Medical Editors & Writers CHARLESTOWN, Mass.--(BUSINESS WIRE)--May 8, 2002 BioTransplant Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTRN) will hold a live web cast to provide a financial company update, in conjunction with BioTransplant's 2002 first quarter results update expected to be issued on May 13, 2002. You are invited to listen to the web cast, which will be broadcast live over the Internet on Monday, May 13th at 10:00 a.m. ET, with Dr. Elliot Lebowitz, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Richard Capasso, VP of Finance, Treasurer of BioTransplant.
What: BioTransplant's 2002 First Quarter Results web cast
When: Monday, May 13, 2002 at 10:00 am ET
Where: www.biotransplant.com
How: Live over the Internet -- Simply log on to the web
at www.biotransplant.com
This call will not be archived or available for replay. About BioTransplant BioTransplant Incorporated, headquartered in Charlestown, Mass., is developing a portfolio of products for application in a range of medical conditions, including treatment of cancer and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , organ and tissue transplantation, for which current therapies are inadequate. Siplizumab (MEDI-507), a lead product we exclusively licensed to MedImmune, is in Phase II clinical trials for the treatment of psoriasis. In addition, the Company is developing the AlloMune(TM) System which is designed to treat a variety of hematologic malignancies, and its distribution partner Gambro BCT BCT Brigade Combat Team BCT Basic Combat Training BCT Best Conventional Pollutant Control Technology (EPA) BCT Business Cards Tomorrow BCT Banque Centrale de Tunisie (Central Bank of Tunisia) markets the Eligixr Cell Separation System family of cell separation products in Europe for use in bone marrow, stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. and donor leukocyte leukocyte (l  `kəsīt'): see blood. leukocyte or white blood cell or white corpuscle transplants. BioTransplant is also targeting the use of the Eligix Cell Separation Systems as a component of the AlloMune(TM) System, which, along with its proprietary monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases. For more information on BioTransplant, please visit: http://www.biotransplant.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion